Hydroxyurea's effects on growth and fertility in young people with sickle cell anemia
Follows young people with sickle cell anemia taking hydroxyurea over time.
Plain-language title generated from the registry record
Registry title: Serial Assessment of Fertility Experiences
Key facts
- Where
- Mwanza, TanzaniaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with sickle cell anemia who are enrolled on the EXTEND or SACRED study. It follows their growth, puberty, fertility and pregnancy outcomes with hydroxyurea.
- Age
- At least 8 years old.
- Sex
- All sexes can join.
- Disease stage
- Documented sickle cell anemia (SCA).
- Earlier treatment
- Cannot have had other treatments for sickle cell disease in the past 6 months.
Main reasons for not taking part
- Currently taking part in another treatment study (other than EXTEND or SACRED)
- Other treatments for sickle cell disease in the past 6 months
- Unable to take part in all parts of the study
Read by machine on 9 November 2026.
Where in Tanzania
- Buganda Medical CentreMwanza, TanzaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Children's Hospital Medical Center, Cincinnati
- Trial code
- NCT07116772
- Record updated
- 4 February 2026
- Original description
The SAFE study is a long-term research project that watches people with sickle cell anemia (SCA) over time. The main goal is to see how a medicine called hydroxyurea affects their growth, puberty, and ability to have children. A second goal is to see how hydroxyurea affects pregnancy outcomes, by comparing people who take the medicine to those who don't.Read full original descriptionShow less
A Prospective Longitudinal Study of Growth, Development, Fertility and Reproductive Outcomes Among Adolescents and Young Adults With Sickle Cell Anemia With Hydroxyurea
The SAFE study is a long-term research project that watches people with sickle cell anemia (SCA) over time. The main goal is to see how a medicine called hydroxyurea affects their growth, puberty, and ability to have children. A second goal is to see how hydroxyurea affects pregnancy outcomes, by comparing people who take the medicine to those who don't.
Inclusion: Patients with documented sickle cell anemia (SCA); At least 8 years of age at the time of enrollment; Enrolled on the EXTEND or SACRED study; Provide informed consent; Able to take part in all parts of the study, including treatments, check-ups, and follow-up visits.
Exclusion: Currently taking part in another treatment study (not EXTEND or SACRED); Has received other treatments for sickle cell disease in the past 6 months.